PDF下载 ( 1118 KB)
Strategic exploration of alternative sources to overcome the shortage of liver organ donors
-
摘要:
<正>世界卫生组织发布的数据显示,中国有1.4亿乙型和丙型肝炎病毒携带者,约占全球乙、丙两型肝炎病毒携带者的28%;其中有3200万慢性活动性肝病患者;年发病人数3000万,每年有40万人死于病毒性肝病[1]。由于社会生活方式和饮食习惯的改变,过去西方国家较多发的脂肪肝、药物性和酒精性肝炎、肝硬化等肝病也在我国逐渐增多[2]。另外我国现有29.7万肝癌患者,占全球肝癌患者总和的一半以上[3]。
-
Key words:
- liver transplantation /
- cell transplantation /
- liver
-
[1]WHO Publicootion.Hepatitis B vaccines:WHO position paper-recomm-endation[J].Vaccine, 2010, 28 (3) :589-590. [2]Lu XL, Luo JY, Tao M, et al.Risk factors for alcoholic liver dis-ease in China[J].World J Gastroenterol, 2004, 10 (16) :2423-2426. [3]Si CW.Current status and problem of chronic hepatitis B (in Chi-nese) [J].Clin Med J, 2006, 4:1-2. [4]Liu J, Fan D.“Hepatitis B in China”[J].The Lancet, 2007, 369 (9573) :1582-1583. [5]Crespo G, Mario Z, Navasa M, et al.Viral hepatitis in livertransplantation[J].Gastroenterology, 2012, 142 (6) :1373-1383. [6]Li X, Xu WF.China’s efforts to shed its title of“leader in liv-er diseases”[J].Drug Discov Ther, 2007, 1 (2) :84-85. [7]Fukumitsu K, Yagi H, Soto-Gutierrez A.Bioengineering inorgan transplantation:targeting the liver[J].TransplantationProceedings, 2011, 43 (6) :2137-2138. [8]Merion RM.Current status and future of liver transplantation[J].Semin Liver Dis, 2010, 30 (4) :411-421. [9]Calne R.Challenges of organ transplantation[J].Transplan-tation Proc, 2005, 37 (5) :1979-1983. [10]Klein AS, Messersmith EE, Ratner LE, et al.Organ donationand utilization in the United States, 1999-2008[J].Am JTransplant, 2010, 10 (4 pt 2) :973-986. [11]高妍, 张彦玲.“万能猪”开启异种移植时代[J].热点聚焦, 2012, 57:30-33. [12]Glazier AK.The principles of gift law and the regulation of or-gan donation[J].Transpl Int, 2011, 24 (4) :368-372. [13]Martínez-Alarcón L, Ríos A, Sánchez J, et al.Evaluation ofthe law of presumed consent after brain death by Spanishjournalism students[J].Transplant Proc, 2010, 42 (8) :3109-3112. [14]Roels L, Rahmel A.The European experience[J].TransplInt, 2011, 24 (4) :350-367. [15]Rosenblum AM, Horvat LD, Siminoff LA, et al.The authorityof next-of-kin in explicit and presumed consent systemsfor deceased organ donation:an analysis of 54 nations[J].Nephrol Dial Transplant, 2012, 27 (6) :2533-2546. [16]Rees M.Presumed consent for organ donation[J].Ann RColl Surg Engl, 2011, 93 (7) :565. [17]Fabre J, Murphy P, Matesanz R.Presumed consent:a dis-traction in the quest for increasing rates of organ donation[J].BMJ, 2010, 341 (2) :c4973. [18]López-Navidad A, Caballero F.Extended criteria for organacceptance.Strategies for achieving organ safety and for in-creasing organ pool[J].Clin Transplant, 2003, 17 (4) :308-324. [19]Halon A, Patrzalek D, Rabczynski J.Hepatic steatosis in livertransplant donors:rare phenomenon or common feature ofdonor population?[J].Transplant Proc, 2006, 38 (1) :193-195. [20]Kitchens WH, Kitchens.Domino liver transplantation:indica-tions, techniques, and outcomes[J].TransplantationReivews, 2011, 25 (4) :167-177. [21]Gondolesi GE, Roayaie S, Munoz L, et al.Adult living donorliver transplantation for patients with hepatocellular carcino-ma:extending UNOS priority criteria[J].Ann Surg, 2004, 239 (2) :142-149. [22]Fisher RA, Strom SC.Human hepatocyte transplantation:world-wide results[J].Transplantation, 2006, 82 (4) :441-449. [23]Yamanouchi K, Zhou H, Roy-Chowdhury N, et al.Hepaticirradiation augments engraftment of donor cells followinghepatocyte transplantation[J].Hepatology, 2009, 49 (1) :258-267. [24] Petersen J, Burda MR, Dandri M, et al.Transplantation ofhuman hepatocytes in immunodeficient UPA mice:a modelfor the study of hepatitis B virus[J].Methods Mol Med, 2004, 96:253-260. [25]Dolle L, Best J, Mei J, et al.The quest for liver progenitorcells:a practical point of view[J].J Hepatol, 2010, 52 (1) :117-129. [26]Hu M, Kurobe M, Jeong YJ, et al.Wnt/beta-catenin sig-naling in murine hepatic transit amplifying progenitor cells[J].Gastroenterology, 2007, 133 (5) :1579-1591. [27]Piscaglia AC, Campanale M, Gasbarrini A, et al.Stem cell-based therapies for liver diseases:state of the art and newperspectives[J].Stem Cells Int, 2010, 2010:259461-259471. [28]Kaibori M, Adachi Y, Shimo T, et al.Stimulation of liver re-generation after hepatectomy in mice by injection of bonemarrow mesenchymal stem cells via the portal vein[J].Transplant Proc, 2012, 44 (4) :1107-1109. [29]Schneider MK, Seebach JD.Xenotransplantation literature up-date June-October[J].Xenotransplantation, 2010, 17 (6) :481-488. [30]Yagi S, Iida T, Hori T, et al.Effect of portal haemodynamicson liver graft and intestinal mucosa after small-for-size livertransplantation in Swine[J].Eur Surg Res, 2012, 48 (3) :163-170. [31]Dandri M, Burda MR, Trk E, et al.Repopulation of mouseliver with human hepatocytes and in vivo infection with hepa-titis B virus[J].Hepatology, 2001, 33 (4) :981-988. [32]Sacci JB Jr, Schriefer ME, Resau JH, et al.Mouse modelfor exoerythrocytic stages of Plasmodium falciparum malariaparasite[J].Proc Natl Acad Sci U S A, 1992, 89 (9) :3701-3705. [33]Ohashi K, Marion PL, Nakai H, et al.Sustained survival ofhuman hepatocytes in mice:A model for in vivo infectionwith human hepatitis B and hepatitis delta viruses[J].NatMed, 2000, 6 (3) :327-331. [34]Ilan E, Burakova T, Dagan S, et al.The hepatitis B virus-trimera mouse:a model for human HBV infection and evalua-tion of anti-HBV therapeutic agents[J].Hepatology, 1999, 29 (2) :553-562. [35]Carpentier B, Gautier A, Legallais C.Artificial and bioartificialliver devices:present and future[J].Gut, 2009, 58 (12) :1690-1702. [36]Hammond JS, Gilbert TW, Howard D, et al.Scaffolds con-taining growth factors and extracellular matrix induce hepato-cyte proliferation and cell migration in normal and regenera-ting rat liver[J].J Hepatol, 2011, 54 (2) :279-287. [37]Crapo PM, Gilbert TW, Badylak SF.An overview of tissue andwhole organ decellularization processes[J].Biomaterials, 2011, 32 (12) :3233-3243. [38]Melkonian AD, Gaylor JD, Cousins RB, et al.Culture of adifferentiated liver cell line, Hep G2, in serum with applica-tion to a bioartificial liver:effect of supplementation of serumwith amino acids[J].Artif Organs, 1994, 18 (8) :611-617. [39]Harimoto N, Taketomi A, Kitagawa D, et al.The newly es-tablished human hepatocyte cell line:application for the bio-artificial liver[J].J Hepatol, 2005, 42 (4) :557-564. [40]Kobayashi N, Noguchi H, Westerman KA, et al.Cre/loxP-based reversible immortalization of human hepatocytes[J].Cell Transplant, 2001, 10 (4-5) :383-386. [41]Kobayashi N, Okitsu T, Nakaji S, et al.Hybrid bioartificial liv-er:establishing a reversibly immortalized human hepatocyteline and developing a bioartificial liver for practical use[J].JArtif Organs, 2003, 6 (4) :236-244. -
本文二维码
计量
- 文章访问数: 3215
- HTML全文浏览量: 14
- PDF下载量: 667
- 被引次数: 0
下载:
